File downloaded on 2026-11-23
Source URL: https://medicines.health.europa.eu/veterinary/en/600000073041

Virbagen canis LT

Authorised

- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
- Rabies virus, strain VP12, Inactivated

Product identification

Medicine name:
Virbagen canis LT

Active substance:
Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

Rabies virus, strain VP12, Inactivated

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

833000000.00 cells / 1.00 Dose

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
833000000.00 cells / 1.00 Dose

Rabies virus, strain VP12, Inactivated
1.00 international unit(s) / 1.00 Dose

Pharmaceutical form:
Solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AL01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Package description:
Available only in German

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac Tierarzneimittel GmbH

Marketing authorisation date:
22/12/2005

Manufacturing sites for batch release:
Virbac

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
139a/82

Date of authorisation status change:
24/11/2010

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 9/09/2024
Updated on: 14/03/2026
Download

2613687-paren-20170125.pdf.pdf